David Shaw - Concepedia

Author

David Shaw

Also Known As

D M Shaw, D. M. Shaw, D. Shaw, D.M Shaw, D.M. Shaw, D.Michael Shaw, David M Shaw, David M. SHAW, David M. Shaw, David Shaw

Publications

1.7K

Citations

H-Index

Concepts

All Affiliations

Cancer Research UK Manchester Institute The Christie NHS Foundation Trust Oxford BioMedica (United Kingdom)Science Oxford Syngenta (United Kingdom)

About

David Shaw is an author at Cancer Research UK Manchester Institute specializing in medicine, immunology, and immunotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	15	15	903
2	Allergy	5	5	172
3	Natural Sciences	3	3	98
4	Health Sciences	2	2	83
5	Engineering	1	1	45

David Shaw

Publications

1.6K

Citations

H-Index

Page 1

	Year	Citations
The Role of Extracellular Spacer Regions in the Optimal Design of Chimeric Immune Receptors Ryan D. Guest, Robert E. Hawkins, Eleanor J. Cheadle, Journal of Immunotherapy Extracellular Spacer RegionsT-regulatory CellImmunologyImmunodominanceImmunologic Mechanism	2005	304
Selective Inhibition of Na <sub>V</sub> 1.8 with VX-548 for Acute Pain J. W. Jones, Darin Correll, Sandra Lechner, New England Journal of Medicine	2023	221
Heparin and heparan sulfate bind interleukin-10 and modulate its activity Shahram Salek‐Ardakani, John R. Arrand, David Shaw, Blood	2000	140
Instruments for oral disease-intervention strategies: recombinant Lactobacillus casei expressing tetanus toxin fragment C for vaccination or myelin proteins for oral tolerance induction in multiple sclerosis C.B.M. Maassen, Jon D. Laman, M.‐J. Heijne Den Bak‐Glashouwer, Vaccine VaccinationMyelin ProteinsOral Tolerance InductionPathogenesisImmunology	1999	124
Engineering the microflora to vaccinate the mucosa: serum immunoglobulin G responses and activated draining cervical lymph nodes following mucosal application of tetanus toxin fragment C‐expressing lactobacilli David Shaw, B. GaerthÉ, Rob J. Leer, Immunology	2000	123
Priming of CD4+ and CD8+ T cell responses using a HCV core ISCOMATRIX™ vaccine: A phase I study in healthy volunteers Debbie Drane, Eugene Maraskovsky, Rebecca A. Gibson, Human Vaccines	2009	112
A Novel Strategy To Reduce the Immunogenicity of Biological Therapies J Somerfield, Grant Hill-Cawthorne, Andrew C. Lin, The Journal of Immunology Therapeutic MabImmunologyBiological TherapiesBiological TherapyImmunotherapy	2010	64
Attenuated recombinant vaccinia virus expressing oncofetal antigen (tumor-associated antigen) 5T4 induces active therapy of established tumors. Kate Mulryan, Matthew G. Ryan, Kevin A. Myers, PubMed ImmunologyPathologyImmunotherapyViral OncologyOncofetal Antigen	2002	61
A phase II study of a 5T4 oncofoetal antigen tumour-targeted superantigen (ABR-214936) therapy in patients with advanced renal cell carcinoma David Shaw, Natalia Connolly, Poulam M. Patel, British Journal of Cancer	2007	59
CXCR4 Mediated Chemotaxis Is Regulated by 5T4 Oncofetal Glycoprotein in Mouse Embryonic Cells Thomas D. Southgate, Owen J. McGinn, Fernanda Castro, PLoS ONE Cxcr4 Membrane ExpressionCell ProliferationCancer BiologyCellular PhysiologyTumor Biology	2010	54

Page 1